Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
First Claim
Patent Images
1. A sustained-release intraocular drug delivery system comprising:
- a therapeutic component comprising an antiangiogenic polypeptide component; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
4 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure relates to novel sustained-release intraocular drug delivery systems and improvements in the treatment of retinopathies. In particular, fibronectin scaffold domain proteins that selectively inhibit VEGFR-2 are contemplated.
120 Citations
9 Claims
-
1. A sustained-release intraocular drug delivery system comprising:
- a therapeutic component comprising an antiangiogenic polypeptide component; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye. - View Dependent Claims (2, 3, 4, 5, 6, 7)
- a therapeutic component comprising an antiangiogenic polypeptide component; and
-
8. A sustained-release intraocular drug delivery system comprising:
- a therapeutic component comprising an antiangiogenic polypeptide component, wherein the therapeutic component is selected from the group consisting of C7S100 and C7C100; and
a polymeric component associated with the therapeutic component to permit the therapeutic component to be released into the interior of an eye of an individual at a therapeutically effective dosage for a period of time after the drug delivery system is placed in the eye.
- a therapeutic component comprising an antiangiogenic polypeptide component, wherein the therapeutic component is selected from the group consisting of C7S100 and C7C100; and
-
9. A method of treating a retinopathy, the method comprising administering, to a patient in need thereof, a therapeutically effective amount of a polypeptide that binds to human VEGFR-2, the polypeptide comprising between about 80 and about 150 amino acids that have a structural organization comprising:
-
i) at least five to seven beta strands or beta-like strands distributed among at least two beta sheets, and ii) at least one loop portion connecting two strands that are beta strands or beta-like strands, which loop portion participates in binding to VEGFR-2, wherein the polypeptide binds to an extracellular domain of the human VEGFR-2 protein with a dissociation constant (KD) of less than 1×
10−
6 M and inhibits VEGFR-2 mediated angiogenesis.
-
Specification